Conor Farrington1, Zoe Stewart2,3, Roman Hovorka2, Helen Murphy2,4. 1. 1 THIS Institute, University of Cambridge, Cambridge, UK. 2. 2 Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK. 3. 3 Department of Obstetrics and Gynaecology, University of Cambridge, Cambridge, UK. 4. 4 Norwich Medical School, University of East Anglia, Norwich, UK.
Abstract
AIMS: Closed-loop insulin delivery has the potential to improve day-to-day glucose control in type 1 diabetes pregnancy. However, the psychosocial impact of day-and-night usage of automated closed-loop systems during pregnancy is unknown. Our aim was to explore women's experiences and relationships between technology experience and levels of trust in closed-loop therapy. METHODS: We recruited 16 pregnant women with type 1 diabetes to a randomized crossover trial of sensor-augmented pump therapy compared to automated closed-loop therapy. We conducted semistructured qualitative interviews at baseline and follow-up. Findings from follow-up interviews are reported here. RESULTS: Women described benefits and burdens of closed-loop systems during pregnancy. Feelings of improved glucose control, excitement and peace of mind were counterbalanced by concerns about technical glitches, CGM inaccuracy, and the burden of maintenance requirements. Women expressed varied but mostly high levels of trust in closed-loop therapy. CONCLUSIONS: Women displayed complex psychosocial responses to day-and-night closed-loop therapy in pregnancy. Clinicians should consider closed-loop therapy not just in terms of its potential impact on biomedical outcomes but also in terms of its impact on users' lives.
RCT Entities:
AIMS: Closed-loop insulin delivery has the potential to improve day-to-day glucose control in type 1 diabetes pregnancy. However, the psychosocial impact of day-and-night usage of automated closed-loop systems during pregnancy is unknown. Our aim was to explore women's experiences and relationships between technology experience and levels of trust in closed-loop therapy. METHODS: We recruited 16 pregnant women with type 1 diabetes to a randomized crossover trial of sensor-augmented pump therapy compared to automated closed-loop therapy. We conducted semistructured qualitative interviews at baseline and follow-up. Findings from follow-up interviews are reported here. RESULTS:Women described benefits and burdens of closed-loop systems during pregnancy. Feelings of improved glucose control, excitement and peace of mind were counterbalanced by concerns about technical glitches, CGM inaccuracy, and the burden of maintenance requirements. Women expressed varied but mostly high levels of trust in closed-loop therapy. CONCLUSIONS:Women displayed complex psychosocial responses to day-and-night closed-loop therapy in pregnancy. Clinicians should consider closed-loop therapy not just in terms of its potential impact on biomedical outcomes but also in terms of its impact on users' lives.
Entities:
Keywords:
closed-loop; day-and-night; pregnancy; type 1 diabetes
Authors: Mary C M Macintosh; Kate M Fleming; Jaron A Bailey; Pat Doyle; Jo Modder; Dominique Acolet; Shona Golightly; Alison Miller Journal: BMJ Date: 2006-06-16
Authors: Melissa M Kallas-Koeman; Jason M Kong; Jennifer A Klinke; Sonia Butalia; Abhay K Lodha; Ken I Lim; Qiuli M Duan; Lois E Donovan Journal: Diabetologia Date: 2014-01-17 Impact factor: 10.122
Authors: Graham R Law; George T H Ellison; Anna L Secher; Peter Damm; Elisabeth R Mathiesen; Rosemary Temple; Helen R Murphy; Eleanor M Scott Journal: Diabetes Care Date: 2015-04-23 Impact factor: 19.112
Authors: Zoe A Stewart; Malgorzata E Wilinska; Sara Hartnell; Rosemary C Temple; Gerry Rayman; Katharine P Stanley; David Simmons; Graham R Law; Eleanor M Scott; Roman Hovorka; Helen R Murphy Journal: N Engl J Med Date: 2016-08-18 Impact factor: 91.245
Authors: Michael J A Maresh; Valerie A Holmes; Christopher C Patterson; Ian S Young; Donald W M Pearson; James D Walker; David R McCance Journal: Diabetes Care Date: 2014-11-03 Impact factor: 19.112
Authors: J Kropff; J DeJong; S Del Favero; J Place; M Messori; B Coestier; A Farret; F Boscari; S Galasso; A Avogaro; D Bruttomesso; C Cobelli; E Renard; L Magni; J H DeVries Journal: Diabet Med Date: 2016-10-28 Impact factor: 4.359
Authors: Katarina Braune; Rayhan A Lal; Lenka Petruželková; Gary Scheiner; Per Winterdijk; Signe Schmidt; Linda Raimond; Korey K Hood; Michael C Riddell; Timothy C Skinner; Klemens Raile; Sufyan Hussain Journal: Lancet Diabetes Endocrinol Date: 2021-11-13 Impact factor: 32.069